MedTrace Logo

Herbal Patch for Overactive Bladder

NCT03532789 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2019-10-25

No results posted yet for this study

Summary

Overactive bladder is a clinical syndrome characterized by frequency, with or without urge incontinence, urgency, and nocturia, which affect patients' sleeping quality and rehabilitation program progressing. Current treatments include behavioral therapy (eg, life style adjustment, bladder training, pelvic floor muscle therapy) and medication. Antimuscarinic agents is the most common medications prescribed for OAB, but patients often have side effects like dry mouth and constipation. And there were plenty of herbal medicine which are beneficial to urine frequency and voiding dysfunction in ancient Chinese medicine books and records. In human trial, 62 Subjects diagnosed as overactive bladder will be enrolled and treated with Cinnamon patch. After treatment we will estimate the efficacy and record adverse events to conduct statistically analysis.

Conditions

  • Overactive Bladder Syndrome

Interventions

DRUG

herbal patch

One patch with medicine should be applied to the skin every other day within two weeks

DRUG

placebo patch

One patch without medicine should be applied to the skin every other day within two weeks

Sponsors & Collaborators

  • En Chu Kong Hospital

    lead OTHER

Principal Investigators

  • LIH-LIAN CHEN, MD · attending physician of department of Traditional Chinese medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-14
Primary Completion
2019-10-23
Completion
2019-10-23

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03532789 on ClinicalTrials.gov